TrueBinding
TrueBinding develops novel monoclonal antibody therapeutics for various diseases and offers contract development and manufacturing services to accelerate biopharmaceutical innovation.
Services
TrueBinding offers contract development and manufacturing services aimed at accelerating biopharmaceutical innovation. These services are designed to support the development and production of novel therapeutics, ensuring that partners can bring their biological treatments to market efficiently.
Pipeline of Monoclonal Antibody Therapeutics
TrueBinding is actively developing a pipeline of monoclonal antibody therapeutics aimed at revolutionizing patient care. These targeted treatments address a range of diseases, including neurodegenerative and metabolic disorders, stroke, and oncology. This pipeline reflects the company's commitment to meeting unmet medical needs through innovative solutions.
Expanded Access Program for Alzheimer's Treatment
TrueBinding provides an Expanded Access Program for TB006, particularly for patients suffering from Alzheimer’s Disease who have exhausted all other treatment options. This program underscores the company's dedication to offering solutions for critical health conditions when conventional therapies fall short.
Clinical Trials for Alzheimer's Disease
TrueBinding recently completed a Phase 1b/2a Clinical Trial for TB006 targeting Alzheimer’s Disease. The results indicated potential in slowing or reducing clinical decline, highlighting the therapeutic promise of TB006 in providing a beneficial impact on disease progression.
Corporate Headquarters and Manufacturing Facility
TrueBinding's corporate headquarters are located at 300 Lincoln Centre Drive, Suite 200, Foster City, CA 94404. The company's manufacturing and services facility is situated at 25565 Whitesell Street, Hayward, CA 94545. These locations support the company's operations in research, development, and production.